Norbert Hittel

996 total citations
18 papers, 468 citations indexed

About

Norbert Hittel is a scholar working on Infectious Diseases, Surgery and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Norbert Hittel has authored 18 papers receiving a total of 468 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Infectious Diseases, 7 papers in Surgery and 5 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Norbert Hittel's work include Tuberculosis Research and Epidemiology (7 papers), Antiplatelet Therapy and Cardiovascular Diseases (3 papers) and Peripheral Artery Disease Management (3 papers). Norbert Hittel is often cited by papers focused on Tuberculosis Research and Epidemiology (7 papers), Antiplatelet Therapy and Cardiovascular Diseases (3 papers) and Peripheral Artery Disease Management (3 papers). Norbert Hittel collaborates with scholars based in Germany, United States and United Kingdom. Norbert Hittel's co-authors include Lawrence Geiter, Charles D. Wells, Peter Zhang, Andreas H. Diacon, Peter R. Donald, Amour Venter, Anne Paccaly, M. Hanekom, Rodney Dawson and Kim Narunsky and has published in prestigious journals such as SHILAP Revista de lepidopterología, European Heart Journal and European Respiratory Journal.

In The Last Decade

Norbert Hittel

17 papers receiving 445 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Norbert Hittel Germany 10 209 178 168 72 68 18 468
James Shepherd United States 8 152 0.7× 152 0.9× 339 2.0× 61 0.8× 123 1.8× 19 699
Simona Iftimie Spain 13 153 0.7× 99 0.6× 83 0.5× 82 1.1× 35 0.5× 38 435
Arnaldo Ippoliti Italy 11 63 0.3× 113 0.6× 424 2.5× 39 0.5× 46 0.7× 31 732
Philippe Tellier France 8 191 0.9× 101 0.6× 117 0.7× 85 1.2× 93 1.4× 12 538
A. Gerbes Germany 12 56 0.3× 316 1.8× 207 1.2× 51 0.7× 34 0.5× 37 634
Pier Giorgio Rogasi Italy 15 90 0.4× 96 0.5× 65 0.4× 44 0.6× 123 1.8× 29 402
Ning-Ping Foo Taiwan 10 77 0.4× 80 0.4× 115 0.7× 121 1.7× 15 0.2× 16 463
Wen Gao China 15 51 0.2× 121 0.7× 339 2.0× 66 0.9× 14 0.2× 35 609
Kersti Oselin Estonia 15 114 0.5× 102 0.6× 72 0.4× 70 1.0× 13 0.2× 41 721
M Shield United Kingdom 10 149 0.7× 134 0.8× 205 1.2× 35 0.5× 92 1.4× 15 608

Countries citing papers authored by Norbert Hittel

Since Specialization
Citations

This map shows the geographic impact of Norbert Hittel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Norbert Hittel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Norbert Hittel more than expected).

Fields of papers citing papers by Norbert Hittel

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Norbert Hittel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Norbert Hittel. The network helps show where Norbert Hittel may publish in the future.

Co-authorship network of co-authors of Norbert Hittel

This figure shows the co-authorship network connecting the top 25 collaborators of Norbert Hittel. A scholar is included among the top collaborators of Norbert Hittel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Norbert Hittel. Norbert Hittel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Nasiri, Mohammad Javad, Maryam Amiri, Giovanni Sotgiu, et al.. (2025). 15-year trends in efficacy and effectiveness of treatment outcomes in drug-resistant pulmonary TB. PubMed. 2(4). 187–198.
2.
Schönfeld, Nicolas, Manfred Danilovitš, Skaidrius Miliauskas, et al.. (2024). Real-life use of delamanid: results from the European post-authorisation safety study. SHILAP Revista de lepidopterología. 1(6). 274–278. 1 indexed citations
3.
Gillespie, Stephen H., Andrew R. DiNardo, Sophia B. Georghiou, et al.. (2024). Developing biomarker assays to accelerate tuberculosis drug development: defining target product profiles. The Lancet Microbe. 5(9). 100869–100869. 3 indexed citations
4.
Diel, Roland, Norbert Hittel, & Albert Nienhaus. (2021). Point-of-Care COVID-19 Antigen Testing in Exposed German Healthcare Workers—A Cost Model. International Journal of Environmental Research and Public Health. 18(20). 10767–10767. 4 indexed citations
5.
Breitscheidel, Lusine, et al.. (2020). Compassionate use of delamanid in adults and children for drug-resistant tuberculosis: 5-year update. European Respiratory Journal. 57(5). 2002483–2002483. 8 indexed citations
6.
Gupta, Rajesh, Charles D. Wells, Norbert Hittel, Jeffrey Hafkin, & Lawrence Geiter. (2016). Delamanid in the treatment of multidrug-resistant tuberculosis. The International Journal of Tuberculosis and Lung Disease. 20(12). 33–37. 16 indexed citations
7.
Diel, Roland, Norbert Hittel, & Tom Schaberg. (2015). Cost effectiveness of treating multi-drug resistant tuberculosis by adding Deltyba™ to background regimens in Germany. Respiratory Medicine. 109(5). 632–641. 18 indexed citations
8.
Diacon, Andreas H., Rodney Dawson, M. Hanekom, et al.. (2011). Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients. The International Journal of Tuberculosis and Lung Disease. 15(7). 949–954. 157 indexed citations
9.
Pande, Reena L., William R. Hiatt, Peter Zhang, Norbert Hittel, & Mark A. Creager. (2010). A pooled analysis of the durability and predictors of treatment response of cilostazol in patients with intermittent claudication. Vascular Medicine. 15(3). 181–188. 70 indexed citations
10.
Lundahl, Joachim, A.‐K. Ulfgren, Kerstin Elvin, et al.. (2006). Down-regulation of interferon-γ parallels clinical response to selective leukocyte apheresis in patients with inflammatory bowel disease: a 12-month follow-up study. International Journal of Colorectal Disease. 21(6). 493–504. 35 indexed citations
11.
Nenoff, Pietro, U.‐F. Haustein, & Norbert Hittel. (2004). Activity of Nadifloxacin (OPC-7251) and Seven Other Antimicrobial Agents against Aerobic and Anaerobic Gram-Positive Bacteria Isolated from Bacterial Skin Infections. Chemotherapy. 50(4). 196–201. 30 indexed citations
12.
Hittel, Norbert & Richard Donnelly. (2002). Treating peripheral arterial disease in patients with diabetes. Diabetes Obesity and Metabolism. 4(s2). S26–31. 23 indexed citations
13.
Rendell, Marc, et al.. (2002). Cilostazol Treatment of Claudication in Diabetic Patients. Current Medical Research and Opinion. 18(8). 479–487. 15 indexed citations
14.
15.
Rosenthal, J., et al.. (1996). Pranidipine, a novel calcium antagonist, once daily, for the treatment of hypertension: A multicenter, double-blind, placebo-controlled dose-finding study. Cardiovascular Drugs and Therapy. 10(1). 59–66. 5 indexed citations
16.
Bojar, R.A., Norbert Hittel, W.J. Cunliffe, & K.T. Holland. (1995). Direct Analysis of Resistance in the Cutaneous Microflora during Treatment of Acne Vulgaris with Topical 1% Nadifloxacin and 2% Erythromycin. Drugs. 49(Supplement 2). 164–167. 16 indexed citations
17.
Ruppert, M., J. Alan Diehl, R. Kolloch, et al.. (1991). Short-term dietary sodium restriction increases serum lipids and insulin in salt-sensitive and salt-resistant normotensive adults.. PubMed. 69 Suppl 25. 51–7. 52 indexed citations
18.
Broadhurst, P., et al.. (1991). Prolonged hypotensive effect of OPC-13340: a new, once-daily calcium channel blocking drug. European Heart Journal. 12(3). 434–438. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by James Shepherd Breakdown of academic impact, for papers by Simona Iftimie Breakdown of academic impact, for papers by Arnaldo Ippoliti Breakdown of academic impact, for papers by Philippe Tellier Breakdown of academic impact, for papers by A. Gerbes Breakdown of academic impact, for papers by Pier Giorgio Rogasi Breakdown of academic impact, for papers by Ning-Ping Foo Breakdown of academic impact, for papers by Wen Gao Breakdown of academic impact, for papers by Kersti Oselin Breakdown of academic impact, for papers by M Shield
Rankless by CCL
2026